Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction.

Background: Endostatin is a circulating endogenous angiogenesis inhibitor preventing neovascularization. Previous studies demonstrated the prognostic value of Endostatin among patients with heart failure with reduced ejection fraction (HFrEF). However, the role of Endostatin among patients with heart failure with preserved ejection fraction (HFpEF) remains unclear.

Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.

Background: Insulin-like growth factor binding protein-7 (IGFBP-7) modulates the biological activities of insulin-like growth factor-1 (IGF-1). Previous studies demonstrated the prognostic value of IGFBP-7 and IGF-1 among patients with systolic heart failure (HF). This study aimed to evaluate the IGF1/IGFBP-7 axis in HF patients with preserved ejection fraction (HFpEF).

[Indicators of process and outcome quality in the context of multicenter quality management in cardiac rehabilitation].

From the point of view of quality management in general and clinic comparisons in particular, indicators of outcome quality must be chosen in such a way that conclusions regarding the quality of rehabilitational care processes can be drawn. Moreover, these indicators should reflect disease characteristics which, on the one hand, are relevant in terms of prognoses and, on the other, provide indications for rehabilitation therapy. Predictors of rehabilitation success need to be differentiated analytically in order to safeguard the adjustment of risks when, for instance, clinics are being compared.